BMXXY
bioMérieux S.A. develops and produces in vitro diagnostic solutions for the diagnosis of infectious diseases in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers systems, which use biological samples to diagnose infectious diseases, cardiovascular pathologies, and various cancers; and microbiological testing of manufacturing primarily for food, pharmaceutical, cosmetics, and veterinary sectors. It serves clinical and hospital laboratories, physicians, blood banks, and industrial control laboratories. The company was formerly known as B-D Mérieux. bioMérieux S.A. was founded in 1963 and is headquartered in Marcy l'Etoile, France. bioMérieux S.A. is a subsidiary of Institut Mérieux SA.
| Period | EPS | Revenue | FCF |
|---|---|---|---|
| 2025 Q4 | 0.20 | $2.0B | $296M |
| 2025 Q2 | 0.14 | $2.0B | $165M |
| 2024 Q4 | 0.18 | $2.1B | $275M |
| 2024 Q2 | 0.18 | $1.9B | $47M |
| 2023 Q4 | 0.16 | $1.9B | $110M |
| 2023 Q2 | 0.14 | $1.8B | -$2M |
| 2022 Q4 | 0.19 | $1.9B | $190M |
| 2022 Q2 | 0.19 | $1.7B | -$2M |